We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA.
- Authors
Flinn, I. W.; Jacobson, C. A.; Nastoupil, L. J.; Morschhauser, F.; Davies, A.; Buske, C.; Corradini, P.; Lopez‐Guillermo, A.; Reshef, R.; Parameswaran, V.; Sehgal, A.; Tees, M.; Lui, C.; Xue, W.; Beygi, S.; Grechko, N.; Bolsue, P.; Giovanetti, A.; To, C.; Nahas, M.
- Abstract
B Introduction: b Patients with relapsed/refractory ( I R i / I R i ) follicular lymphoma (FL) experience progressively shorter remissions with each successive line of therapy, and the disease is largely considered incurable (Batlevi et al. I Blood Cancer J. i 2020). ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA However, outcomes of I R i / I R i FL have improved with the introduction of novel options including chimeric antigen receptor (CAR) T-cell therapy, a highly effective approach with potential to change the treatment paradigm (Jacobson et al. I Lancet Oncol. i 2021; Freedman, Jacobson.
- Subjects
FOLLICULAR lymphoma; STEM cell transplantation
- Publication
Hematological Oncology, 2023, Vol 41, p853
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT31